ClinicalTrials.gg
TerminatedNCT01410695Updated Dec 17, 2018

Masitinib in Refractory Active Rheumatoid Arthritis

A Phase 2/3 interventional study of masitinib 3 mg and masitinib 6.0 mg in Rheumatoid Arthritis (RA), sponsored by AB Science. Terminated at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by AB Science · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

From the registry’s dates

  • Primary completion was Oct 2015, 11 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Arthritis, Rheumatoid with a site in Czechia — 3 open to participants now, 9 under way, 3 of them phase 3. Arthritis, Rheumatoid · Czechia.

Enrollment
94th of 190
324 · median 323
Started
2011
with 13 others
Phase 2/3
2 of 198
none open now
Registered
82nd of 198
by date

Among the 198 studies in Arthritis, Rheumatoid with a site in Czechia, this one is the 94th largest by enrollment of the 190 interventional ones that give a count, is one of 14 that started in 2011, is one of 2 in phase 2/3, and was the 82nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 198 studies in Arthritis, Rheumatoid with a site in Czechia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Arthritis, Rheumatoid with a site in Czechia, or all of them as a file.
02

Study summary

The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis
  • RA
  • masitinib
  • DMARD
  • methotrexate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria for at least 6 months
  2. Patient with ACR functional class I-III
  3. Patient who have active RA
  4. Patient who failed (defined as active RA with stable dose during 3 months) methotrexate or any DMARD including biologics drugs if patients previously failed methotrexate or methotrexate in combination with any DMARD including biologics drugs
  5. Patient with a disease onset at > 16 years of age

Exclusion criteria

Exclusion Criteria:

  1. Patient for whom the use of methotrexate is as per its SPC
  2. Patient with documented fibromyalgia
  3. Patient with lactose intolerance
  4. Patient presenting with cardiac disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    masitinib 3 mg

    masitinib 3 mg/kg/day, tablets, orally, twice a day

    Drug: masitinib 3 mg · Drug: Placebo (methotrexate)

  • Experimental
    masitinib 6.0 mg

    masitinib 6.0 mg/kg/day, tablets, orally, twice a day

    Drug: masitinib 6.0 mg · Drug: Placebo (methotrexate)

  • Active comparator
    methotrexate

    methotrexate at the dose of 15 or 20 mg per week

    Drug: methotrexate · Drug: Placebo (masitinib)

Interventions

06

What researchers measure

Primary outcomes

  1. ACR50

    Time frame: week 24

Secondary outcomes

  1. ACR

    Time frame: week 12

07

Study locations

1 site
  • ARTMEDI UPD s.r.o
    Hostivice, 25301, Czechia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2011
First posted
Aug 5, 2011
Start
Jul 2011
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results delay requested
Dec 12, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01410695
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Aug 5, 2011
Start date
Jul 2011
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Dec 17, 2018

Study contacts

Jacques Tebib, MD
principal investigator · Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion